CLINICAL TRIALS PROFILE FOR SOLRIAMFETOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for solriamfetol hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02806895 ↗ | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA | Completed | Jazz Pharmaceuticals | Phase 2 | 2016-07-05 | This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to obstructive sleep apnea. |
| NCT02806908 ↗ | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy | Completed | Jazz Pharmaceuticals | Phase 2 | 2016-06-01 | This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to narcolepsy. |
| NCT03868943 ↗ | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2021-01-27 | This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas). |
| NCT03868943 ↗ | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma | Recruiting | Wake Forest University Health Sciences | Phase 2 | 2021-01-27 | This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas). |
| NCT04602936 ↗ | Solriamfetol in Binge Eating Disorder | Not yet recruiting | Jazz Pharmaceuticals | Phase 4 | 2020-11-15 | The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED). |
| NCT04602936 ↗ | Solriamfetol in Binge Eating Disorder | Not yet recruiting | Lindner Center of HOPE | Phase 4 | 2020-11-15 | The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED). |
| NCT04622293 ↗ | A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Not yet recruiting | Rochester Center for Behavioral Medicine | Phase 4 | 2021-04-01 | This study is an 8-week single center, randomized, double-blind, placebo-controlled, flexible titration trial evaluating the efficacy of solriamfetol in the treatment of fatigue symptoms in adult patients with chronic fatigue syndrome. Subjects will be randomized to a solriamfetol group or placebo group. The investigators will utilize an intent to treat model and impute data. The overall goal of this study is to determine the efficacy and effectiveness of solriamfetol for treating chronic fatigue syndrome. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for solriamfetol hydrochloride
Condition Name
Clinical Trial Locations for solriamfetol hydrochloride
Trials by Country
Clinical Trial Progress for solriamfetol hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for solriamfetol hydrochloride
Sponsor Name
